Compare MLI & RVMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MLI | RVMD |
|---|---|---|
| Founded | 1917 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.5B | 30.1B |
| IPO Year | 1994 | 2020 |
| Metric | MLI | RVMD |
|---|---|---|
| Price | $60.73 | $203.94 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 19 |
| Target Price | $130.00 | ★ $140.84 |
| AVG Volume (30 Days) | 1.1M | ★ 1.6M |
| Earning Date | 04-21-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.05% | N/A |
| EPS Growth | ★ 29.19 | N/A |
| EPS | ★ 2.21 | N/A |
| Revenue | ★ $4,178,547,000.00 | N/A |
| Revenue This Year | $11.31 | N/A |
| Revenue Next Year | $7.65 | $533.02 |
| P/E Ratio | $28.83 | ★ N/A |
| Revenue Growth | ★ 10.87 | N/A |
| 52 Week Low | $54.50 | $42.18 |
| 52 Week High | $141.90 | $224.31 |
| Indicator | MLI | RVMD |
|---|---|---|
| Relative Strength Index (RSI) | 34.84 | 47.42 |
| Support Level | $59.82 | $198.91 |
| Resistance Level | $71.12 | $222.33 |
| Average True Range (ATR) | 1.85 | 8.08 |
| MACD | 0.45 | -1.85 |
| Stochastic Oscillator | 10.27 | 15.73 |
Mueller Industries Inc makes copper, brass, aluminum, and plastic products. The company reports three business segments: piping systems, industrial metals, and climate. Piping systems, earning majority of the company's revenue, produces tubes, fittings, rods, valves, and other products and operates various firms world-wide. The industrial metals segment manufactures impacts and micro-gauge, brass rod and copper bar products, and brass value-added products. The climate segment produces items used to create temperature-control goods, including valves, twisted tubes, coaxial heat exchangers, and others. Geographically, it operates in USA, UK, Canada, Asia and the Middle East and Mexico.
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.